Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198645 | 0.94 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL2198996 | 0.89 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL2198472 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL2196335 | 0.83 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2196897 | 0.83 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL2198303 | 0.83 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2196091 | 0.83 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2198593 | 0.83 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2198471 | 0.82 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2199523 | 0.82 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | claimed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.